Domača stranNVV1 • FRA
add
Novavax Inc
Prejšnji trg. dan.
8,33 €
Dnevni razpon
7,84 € - 8,12 €
Letni razpon
3,33 € - 23,93 €
Tržna kapitalizacija
1,33 mrd. USD
Povprečni obseg
3,88 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Business Standard
pred 17 urami
Novavax sells Czech manufacturing facility to Novo Nordisk for $200 mn
0,29 %
1,31 %
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 84,51 mio. | −54,80 % |
Stroški poslovanja | 66,95 mio. | −37,70 % |
Čisti dohodek | −121,30 mio. | 7,25 % |
Čista dobičkovnost prihodkov | −143,53 | −105,22 % |
Earnings per share | −0,76 | 39,68 % |
EBITDA | −117,12 mio. | −2,46 % |
Efektivna davčna stopnja | 0,84 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 909,53 mio. | 39,69 % |
Skupna sredstva | 1,71 mrd. | 3,34 % |
Skupne obveznosti | 2,24 mrd. | −4,14 % |
Celoten lastniški kapital | −526,44 mio. | — |
Shares outstanding | 160,18 mio. | — |
Razmerje P/B | −2,53 | — |
Donosnost sredstev | −18,38 % | — |
Donosnost kapitala | 150,12 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −121,30 mio. | 7,25 % |
Denar iz dejavnosti | −144,81 mio. | −265,18 % |
Denar iz naložb | 31,91 mio. | 273,52 % |
Denar iz financiranja | −97,00 tis. | −100,05 % |
Neto sprememba denarnih sredstev | −106,97 mio. | −172,07 % |
Prost denarni tok | −78,48 mio. | −210,04 % |
Vizitka
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
Generalni direktor
Datum ustanovitve
1987
Sedež organizacije
Spletno mesto
Zaposleni
1.543
